Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ciro Celsa

Showing results (71-80 of 115) with videos related to

Pageof 12
Sort By:
The American Journal of Gastroenterology|August 16, 2022
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varicesVincenza Calvaruso, Ciro Celsa, Roberta D'Ambrosio, et al.
JHEP Reports : Innovation in Hepatology|March 14, 2026
PHENO-RAG: An artificial intelligence tool for guideline-informed management decisions in hepatocellular carcinomaCiro Celsa, Mauro Giuffrè, Gabriele Di Maria, et al.
Cancers|February 6, 2021
Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCsBrian I Carr, Vito Guerra, Rossella Donghia, et al.
The Lancet. Oncology|October 22, 2024
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysisAntonio D'Alessio, Bernardo Stefanini, Julia Blanter, et al.
Hepatology (Baltimore, Md.)|February 26, 2026
Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world studyFrancesco Tovoli, Massimo Iavarone, Giuseppe Cabibbo, et al.
Frontiers in Oncology|February 17, 2022
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative TreatmentFilippo Pelizzaro, Selion Haxhi, Barbara Penzo, et al.
Frontiers in Oncology|September 26, 2022
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantationSimone Lasagni, Filippo Leonardi, Alessandra Pivetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2024
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib StudyDavid J Pinato, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 22, 2025
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus BevacizumabLeonardo Stella, Giuseppe Cabibbo, Ciro Celsa, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 27, 2025
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world studyEdoardo G Giannini, Andrea Pasta, Laura Bucci, et al.
Pageof 12

Showing results (71-80 of 115) with videos related to

Sort By:
Pageof 12
The American Journal of Gastroenterology|August 16, 2022
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varicesVincenza Calvaruso, Ciro Celsa, Roberta D'Ambrosio, et al.
JHEP Reports : Innovation in Hepatology|March 14, 2026
PHENO-RAG: An artificial intelligence tool for guideline-informed management decisions in hepatocellular carcinomaCiro Celsa, Mauro Giuffrè, Gabriele Di Maria, et al.
Cancers|February 6, 2021
Identification of Clinical Phenotypes and Related Survival in Patients with Large HCCsBrian I Carr, Vito Guerra, Rossella Donghia, et al.
The Lancet. Oncology|October 22, 2024
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysisAntonio D'Alessio, Bernardo Stefanini, Julia Blanter, et al.
Hepatology (Baltimore, Md.)|February 26, 2026
Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world studyFrancesco Tovoli, Massimo Iavarone, Giuseppe Cabibbo, et al.
Frontiers in Oncology|February 17, 2022
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative TreatmentFilippo Pelizzaro, Selion Haxhi, Barbara Penzo, et al.
Frontiers in Oncology|September 26, 2022
Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantationSimone Lasagni, Filippo Leonardi, Alessandra Pivetti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2024
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib StudyDavid J Pinato, Antonio D'Alessio, Claudia Angela Maria Fulgenzi, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|September 22, 2025
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus BevacizumabLeonardo Stella, Giuseppe Cabibbo, Ciro Celsa, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 27, 2025
Recurrence rate, features, and outcome after hepatocellular carcinoma curative resection or ablation according to the IMbrave050 criteria: a real-world studyEdoardo G Giannini, Andrea Pasta, Laura Bucci, et al.
Pageof 12